{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:27Z","timestamp":1786998447112,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT01063816"],"award-info":[{"award-number":["NCT01063816"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ygyno.2017.12.029","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T22:12:39Z","timestamp":1516140759000},"page":"507-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies"],"prefix":"10.1016","volume":"148","author":[{"given":"Heidi J.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bell-McGuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijith","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.12.029_bb0005","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"BioEssays"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1432-1033.1980.tb04426.x","article-title":"ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells","volume":"104","author":"Wielckens","year":"1980","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0015","first-page":"3441","article-title":"Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers","volume":"43","author":"Hirai","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.2830370402","article-title":"Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma","volume":"37","author":"Tomoda","year":"1991","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1440-1746.2001.02378.x","article-title":"Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma","volume":"16","author":"Shiobara","year":"2001","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0030","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0035","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0040","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/13543770903215883","article-title":"Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?","volume":"19","author":"Papeo","year":"2009","journal-title":"Exp. Opin. Ther. Pat."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0055","author":"American Cancer Society"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0060","doi-asserted-by":"crossref","first-page":"787143","DOI":"10.1155\/2014\/787143","article-title":"BRCA-associated ovarian cancer: from molecular genetics to risk management","volume":"2014","author":"Girolimetti","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0065","first-page":"409","article-title":"Molecular mechanisms of PARP inhibitors in BRCA-related ovarian cancer","volume":"5","author":"Toss","year":"2013","journal-title":"J. Cancer Sci. Ther."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0075","author":"LYNPARZA\u2122"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0080","author":"RUBRACA\u2122"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.2570","article-title":"Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1\/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt)","volume":"32","author":"Puhalla","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.2584","article-title":"Phase I study of ABT-888 in combination with carboplatin and gemcitabine in patients with advanced solid tumors","volume":"31","author":"Bell-McGuinn","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0100","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0105","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1525-1438.2005.15357.x","article-title":"Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma","volume":"15","author":"Rose","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0115","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0120","author":"Gynecologic Cancer Intergroup"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0125","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1307::AID-SIM128>3.0.CO;2-X","article-title":"Adaptive design improvements in the continual reassessment method for phase I studies","volume":"18","author":"Heyd","year":"1999","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0130","author":"European Medicines Agency"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0140","author":"ZEJULA\u2122"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0150","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2015.04.015","article-title":"A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E2511)","volume":"89","author":"Owonikoko","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0160","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00280-015-2876-7","article-title":"A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin\/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)","volume":"76","author":"Mizugaki","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0165","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0170","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/jps.23737","article-title":"Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)","volume":"102","author":"Kikuchi","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0175","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0180","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.12.029_bb0185","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.36","article-title":"A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours","volume":"116","author":"Wilson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.12.029_bb0190","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083","volume":"23","author":"Somlo","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817316207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817316207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T14:27:31Z","timestamp":1603636051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817316207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0090825817316207"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}